Enough money to hold up to September 2019
Carolo biotech also released its report for the third quarter. Bone therapeutics show this cash flow With respect to operational activities, the first nine months of the current fiscal year amounted to EUR 10.47 million. In the same period in 2017, it amounted to 10.14 million.
loss of business At the end of the first three quarters of 2018, 8.96 million reached 8.76 million in the first nine months of 2017. net cash biotechnology reached 8.4m euros by the end of September 2018. Bone Therapists also confirmed their estimates for cash consumption. It is expected to be between 15 and 16 million euros for the 2018 fiscal year. Given the priorities, the company listed in Brussels, Enough cash to reach the end of the third quarter of 2019.
> Bone Therapy